Michael Blanc, MD
Interventional Cardiology · San Angelo, TXNPI 1932139953
Payments from drug & device makers
Across 398 payments — averaging $52.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$6K
- Abbott$4K
- Abiomed$2K
- Penumbra, Inc.$2K
- Philips North America LLC$985
- Medtronic$803
- plus $5K from 29 others
What the payments were for
- Consulting fees$2,65013%
- Speaking & faculty fees$3,00014%
- Travel & lodging$4,57922%
- Food & beverage$10,24449%
- Education$3322%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 9 | $6,071 |
| Abbott | 95 | $3,893 |
| Abiomed | 22 | $2,388 |
| Penumbra, Inc. | 6 | $2,147 |
| Philips North America LLC | 31 | $985 |
| Medtronic(2 entities) | 18 | $803 |
| Novartis | 38 | $647 |
| AstraZeneca | 27 | $527 |
| Shockwave Medical, Inc | 12 | $436 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 25 | $375 |
| Pfizer | 12 | $250 |
| Boston Scientific | 5 | $235 |
| Amgen | 15 | $229 |
| Astellas Pharma US Inc | 4 | $225 |
| Johnson & Johnson | 14 | $223 |
| Cleerly, Inc. | 3 | $220 |
| E.r. Squibb & Sons, L.L.C. | 12 | $194 |
| Merck | 14 | $187 |
| Boehringer Ingelheim | 9 | $146 |
| Heartflow, Inc. | 1 | $134 |
| Sanofi-aventis U.S. LLC | 8 | $130 |
| Tactile Systems Technology Inc | 5 | $74 |
| Novo Nordisk | 1 | $55 |
| Stryker | 1 | $37 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Bayer | 1 | $25 |
| Cardiva Medical, Inc. | 1 | $23 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| United Therapeutics Corporation | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$2,078
- Impella$1,792
- AVEIR$1,198
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$286
- SYMPLICITY G3$284
- Micra$173
- AVVIGO Guidance System$145
- Confirm Rx$142
- (5573) Duo Hybrid$140
- COROFLOW$134
- FFRct$134
- GALLANT$120
- (6575) Coronary Undivided$118
- Cleerly Ischemia$102
- Cleerly Labs$102
- JETi All In One Non-Sterile Kit$101
How this compares
$20,806 in reported general payments places this provider in the 65th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 301 | $315,879 |
| XareltoRivaroxaban | 217 | $184,051 |
| EntrestoSacubitril/Valsartan | 101 | $118,777 |
| JardianceEmpagliflozin | 18 | $29,028 |
| FarxigaDapagliflozin Propanediol | 24 | $20,830 |
| Repatha SureclickEvolocumab | 26 | $14,423 |
| Praluent PenAlirocumab | 22 | $11,399 |
| Ranolazine ErRanolazine | 129 | $9,024 |
| Metoprolol Succinate | 479 | $7,970 |
| Spironolactone | 822 | $6,533 |
| Losartan Potassium | 503 | $5,360 |
| ClopidogrelClopidogrel Bisulfate | 430 | $4,823 |
| Atorvastatin Calcium | 484 | $4,467 |
| Rosuvastatin Calcium | 338 | $4,209 |
| Carvedilol | 422 | $3,894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $250 | $315,879301 claims |
| Johnson & JohnsonXarelto | $223 | $184,051217 claims |
| NovartisEntresto | $647 | $118,777101 claims |
| Boehringer IngelheimJardiance | $146 | $29,02818 claims |
| AstraZenecaFarxiga | $527 | $20,83024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in San Angelo
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
- Cara Ann EastDallas$3M
- Abhijeet DhobleHouston$2.7M
- Jeffrey CarrTyler$2.7M
- M Asad KarimMcKinney$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.